The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population.

A previous genome-wide association study (GWAS) has found that some common variations in the BARD1 gene were associated with neuroblastoma susceptibility especially for high-risk subjects, and the associations have been validated in Caucasians and African-Americans. However, the associations between BARD1 gene polymorphisms and neuroblastoma susceptibility have not been studied among Asians, not to mention Chinese subjects. In the present study, we investigated the association of three BARD1 polymorphisms (rs7585356 G>A, rs6435862 T>G and rs3768716 A>G) with neuroblastoma susceptibility in 201 neuroblastoma patients and 531 controls using TaqMan methodology. Overall, none of these polymorphisms was significantly associated with neuroblastoma susceptibility. However, stratified analysis showed a more profound association between neuroblastoma risk and rs6435862 TG/GG variant genotypes among older children (adjusted OR=1.55, 95% CI=1.04-2.31), and children with adrenal gland-originated disease (adjusted OR=2.94, 95% CI=1.40-6.18), or with ISSN clinical stages III+IV disease (adjusted OR=1.75, 95% CI=1.09-2.84). Similar results were observed for the variant genotypes of rs3768716 A>G polymorphism among these three subgroups. Our results suggest that the BARD1 rs6435862 T>G and rs3768716 A>G polymorphisms may contribute to increased susceptibility to neuroblastoma, especially for the subjects at age ≥12 months, with adrenal gland-originated or with late clinical stage neuroblastoma. These findings need further validation by prospective studies with larger sample size with subjects enrolled from multicenter, involving different ethnicities.

Introduction

Neuroblastoma has been recognized as one of the most commonly diagnosed extracranial solid tumor in infancy, which constitute about 7-10% of all childhood cancers. It is the third leading cause of cancer-related death in children 1. The peak incidence of neuroblastoma is in children, and the median age at diagnosis is around 17 months 2. It may arise anywhere of the sympathetic nervous system, and mainly arise within the abdomen and adrenal medulla 3. The incidence rate of neuroblastoma is about 1 in 7000 live newborns worldwide, and nearly 700 new cases occur per year in the United States 4. It is also one of the most common solid tumors in the Chinese infants, with an incidence rate of approximately 7.7 per million 5. The majority of neuroblastomas are sporadically, and only about 1% of neuroblastoma patients have a family history 6. So far, the etiology of neuroblastoma is not well understood 7. Case-control studies and family studies play important roles in discovering genetic component of the neuroblastoma susceptibility 8. For example, Han et al. 9 performed a case-control study among Chinese with 203 neuroblastoma patients and 411 controls. They found significant association of FAS -1377 G/A and FASL -844 T/C polymorphisms with neuroblastoma susceptibility.

Genome-wide association studies (GWASs) have proven to be a powerful and hypothesis-free method to discover genes that confer susceptibility to complex diseases including cancers 10. To date, five GWASs on the neuroblastoma have been performed, mainly in European descents, and several neuroblastoma susceptibility related loci have been identified 11-15. The first GWAS performed by Maris et al. included 1032 neuroblastoma cases and 2043 controls at the discovery stage, and 720 neuroblastoma cases and 2128 controls in the validation stage 11. They found that three single nucleotide polymorphisms (SNPs) located on chromosome 6p22 were significantly associated with neuroblastoma susceptibility. When the analysis was restricted to only 397 high-risk neuroblastoma cases and 2043 controls 11, they observed new significant association between neuroblastoma susceptibility and six SNPs at 2q35 within the BRCA1 associated RING domain 1 (BARD1) locus. Of them, the rs6435862 T>G and rs3768716 A>G are the two most significant SNPs. The association between GWAS-identified polymorphisms in the BARD1 gene and neuroblastoma susceptibility has been validated in the African-Americans 16 as well as Italians 17, but not in Asians. With this in mind, we carried out the current hospital-based case-control study with a total of 201 neuroblastoma patients and 531 cancer-free controls to explore the association between three GWAS-identified BARD1 gene polymorphisms (rs7585356 G>A, rs6435862 T>G and rs3768716 A>G) and neuroblastoma susceptibility in a Southern Chinese population.

Materials and methods

Study subjects

We enrolled a total of 201 neuroblastoma cases as well as 531 cancer-free controls in this hospital-based case-control study as we described previously 18. All the neuroblastoma cases were newly diagnosed and histopathologically confirmed individuals and recruited from the Guangzhou Women and Children's Medical Center. The cancer-free controls were randomly selected from children receiving a routine physical examination in the same hospital and matched to cases on age and gender (frequency matching). Both of the cases and controls were ethnic Chinese Han subjects. Exclusion criteria were as follows: other types of cancer, secondary/recurrent malignancies, and receipt of chemotherapy or radiotherapy before recruitment. At recruitment, information on each subject (e.g., age, gender and personal medical histories) was collected by structured questionnaire or medical records. This study was approved by the Institutional Review Board of Guangzhou Women and Children's Medical Center. Written informed consent was obtained from all participants or the children's guardians.

Polymorphism analysis

Genomic DNA was mainly extracted from 2 mL blood sample using the TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) according to the manufacturer's instructions. DNA samples were prepared as we described previously 19, 20. Briefly, all the DNA samples were diluted to a concentration of 10 ng/μL and loaded in the 96-well plates. Genotyping for the three GWAS-identified BARD1 SNPs (rs7585356 G>A, rs6435862 T>G, and rs3768716 A>G) 12 was performed in the 384-well plate using Taqman method as published previously 19. As shown in , these three SNPs can also capture an additional of 10 polymorphisms as predicted by SNPinfo software (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm). Moreover, 10% of samples were selected randomly for repeat assay, and the results were 100% concordant.

Statistical analysis

Distributions of demographic variables and genotypes between cases and controls were compared by χ2 test. Goodness-of-fit χ2 test was performed to detect deviation from Hardy-Weinberg equilibrium in controls. Odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for age and gender were used to assess the strength of associations between selected polymorphisms and neuroblastoma susceptibility by using unconditional multivariate logistic regression analysis. All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, NC), with a significance level of 0.05. All tests were two-sided.

Results

Population characteristics

The distributions of the demographic characteristics of the neuroblastoma cases and controls were summarized in . The current study included 201 neuroblastoma patients and 531 age- and gender-matched cancer-free controls. No statistical significant differences were observed in the distributions of age (P=0.788) and gender (P=0.452) between cases and controls. According to INSS criteria 21, 50 (24.88%), 54 (26.87%), 34 (16.92%), 49 (24.38%) and 7 (3.48%) patients had clinical stage I, II, III, IV and 4s neuroblastoma, respectively. In term of tumor site, the neuroblastomas mainly occurred in adrenal glands (N=30, 14.93%), retroperitoneal regions (N=50, 24.86%), and mediastinum (N=80, 39.80%).

Association between BARD1 SNPs and neuroblastoma susceptibility

The genotype frequencies of the three selected SNPs and their associations with neuroblastoma susceptibility were shown in Table . We observed that frequency distributions of all of the BARD1 polymorphisms were consistent with the Hardy-Weinberg equilibrium (P=0.948 for rs7585356 G>A, P=0.205 for rs6435862 T>G, and P=0.415 for rs3768716 A>G polymorphism) in control subjects. We failed to observe any significant association between the rs7585356 G>A polymorphism and neuroblastoma susceptibility (AG vs. GG: adjusted OR=0.91, 95% CI=0.64-1.27; AA vs. GG: adjusted OR=0.61, 95% CI=0.33-1.13; AG/AA vs. GG: adjusted OR=0.85, 95% CI=0.61-1.17 and GG/AG vs. AA: adjusted OR=0.64, 95% CI=0.35-1.16). As to the rs6435862 T>G polymorphism, we found a borderline significant increase in the neuroblastoma risk only for the rs6435862 TG carriers (adjusted OR=1.40, 95% CI=0.98-2.00, P=0.067) when compared to the TT carriers. A similar trend toward increased risk were observed for the rs3768716 heterozygotes (AG vs. AA: adjusted OR=1.40, 95% CI=0.98-2.00, P=0.076). We did not find any significant association for the risk genotypes.

Stratified analysis of BARD1 polymorphisms and neuroblastoma susceptibility

We performed stratified analyses by age, gender, sites of origin, and clinical stages to evaluate the effects of variant genotypes on the risk of neuroblastoma (Table ). Among the girls, carrier of rs7585356 AG or AA genotype had an odds ratio of 0.55 (adjusted OR=0.55, 95% CI=0.33-0.92) for developing neuroblastoma, compared with carriers of GG genotype, suggesting a protective effect of rs7585356 on girls. Moreover, a comparison of homozygotes and heterozygotes versus wild-types indicated that the rs6435862 T>G polymorphism increased the risk of neuroblastoma among the kids older than 12 months (adjusted OR=1.55, 95% CI=1.04-2.31), with tumor in adrenal gland (adjusted OR=2.94, 95% CI=1.40-6.18), and with clinical stages III+IV disease (adjusted OR=1.75, 95% CI=1.09-2.84), when compared to the TT genotype, we observed the TG/GG carriers have an increased neuroblastoma susceptibility. Similar risk effects were observed for the rs3768716 A>G polymorphism among children older than 12 months (adjusted OR=1.54, 95% CI=1.04-2.28), with tumor in adrenal gland (adjusted OR=2.55, 95% CI=1.21-5.37), and with clinical stages III+IV disease (adjusted OR=1.69, 95% CI=1.05-2.72).

Discussion

In the current hospital-based case-control study, we explored the association of three BARD1 gene polymorphisms with neuroblastoma susceptibility in 201 patients and 531 cancer-free controls. To the best of our knowledge, this is the first investigation to validate GWAS-identified SNPs at 2q35 within the BARD1 gene in Southern Chinese population. We found the frequency of the TG/GG genotypes of the rs6435862 T>G polymorphism and the AG/GG genotypes of the rs3768716 A>G polymorphism were significantly higher than that of their respective wide-type genotypes in older subjects, and those with disease originated from adrenal gland or late clinical stage neuroblastoma. The results from the current study suggest that rs6435862 T>G and rs3768716 A>G polymorphisms were significantly associated with neuroblastoma susceptibility for subjects with late clinical stage neuroblastoma, which were consistent with the findings from previous GWAS studies 12.

The BARD1 gene is located at chromosome 2q35, containing 13 exons. This gene encodes a protein that can interact with the N-terminal region of BRCA1 both in vivo and in vitro 22. The BARD1 gene has been recognized as a classically tumor suppressor for the following reasons: 1) it directly interacts with the BRCA1 through their respective RING domains; 2) it plays an important role in double-strand break repair and ubiquitination; 3) it serves as a mediator in the process of apoptosis by binding to and stabilizing p53 23; 4) it also plays roles in the regulation of cell growth, including the products of dominant protooncogenes and tumor suppressor genes 24. Somatically acquired missense BARD1 mutations were observed in the breast and ovarian cancer patients 25. Polymorphisms of BARD1 such as the Cys557Ser may contribute to the susceptibility of breast cancer 26-28. However, a meta-analysis collecting a total of 14 studies with 11870 cases and 7687 controls did not validate the significant association between Cys557Ser mutation and breast cancer risk 29.

SNPs may change the encoding amino acids (non-synonymous SNPs), may be silent (synonymous SNPs), or may occur in the non-coding regions. The non-synonymous SNPs could affect the function and expression levels of genes and consequentially result in disease 30. There are at least 4941 SNPs in the BARD1 gene region (http://www.ncbi.nlm.nih.gov/projects/SNP). Among all the identified BARD1 SNPs, six common polymorphisms have been found to be associated with neuroblastoma susceptibility in a previous GWAS 12. In this study, Capasso et al. only focused on high-risk neuroblastoma patients which were enrolled in their first neuroblastoma GWAS 11, a total of 397 cases and 2043 controls were included in the discover stage, and six SNPs at 2q35 within the BARD1 were found to be significantly associated with increased neuroblastoma susceptibility. A total of 189 cases and 1178 controls were used to further validated the significant SNPs. Of them, the rs6435862 T>G and rs3768716 A>G polymorphism were the most significant for high-risk neuroblastoma patients, with allelic OR of 1.68 for each polymorphism.

In the first replication study carried out among African-Americans, comprising 390 neuroblastoma patients, Latorre et al. 16 found that all of the included SNPs were associated with increased neuroblastoma risk with one exception that they failed to confirm the association of the first GWAS-identified SNPs within the FLJ22536 gene with neuroblastoma susceptibility. In another replication study in Italians with 370 neuroblastoma cases and 809 controls, Capasso et al. 17 proved that the BARD1 SNPs were associated with neuroblastoma susceptibility, and the association was more prominent for high-risk neuroblastoma patients. In the current study, we chose the two most significant SNPs (rs6435862 T>G and rs3768716 A>G) as well as the one located in the 3' UTR region (rs7585356 G>A). We failed to find the significant associations between the selected SNPs and neuroblastoma susceptibility for overall subjects. Interestingly, in the stratified analysis by clinical stages, we found subjects carrying the rs6435862 TG/GG or rs3768716 AG/GG genotypes have a significantly increased risk of developing neuroblastoma among the ISSN clinical stages III/IV neuroblastoma patients. The reason we failed to validate the results from the studies conducted among African-Americans and Italians may be ascribed to the ethnicity difference. For example, the minor allele frequency (MAF) of the rs6435862 T>G was 0.18 for our neuroblastoma cases and 0.16 for the cancer-free controls, 0.34 for African-American cases and 0.26 for and controls, and 0.43 for Italian cases and 0.26 for controls. As to the rs3768716 A>G polymorphism, the MAF for the cases and controls in the current study was 0.21 and 0.18, 0.10 and 0.07 for African-American cases and controls, and 0.35 and 0.23 for Italian cases and controls, respectively. Given the possible differences in the MAF and pattern of linkage disequilibrium among Asians, African-Americans and Caucasians, the effects of the studied genetic susceptibility to neuroblastoma may vary, which may partially explain the failure to validate the significant results from African-Americans and Italians. Besides, the first GWAS also did not detect the association of the BARD1 polymorphisms with neuroblastoma risk in all subjects 11. We speculate that these SNPs within the BARD1 gene may have mild contribution to the development of neuroblastoma. The relatively small sample size of this study might have limited statistical power to detect such mild effect of studied SNPs.

This is the first validation study for the association between BARD1 gene polymorphisms and neuroblastoma susceptibility in Southern Chinese children. There were several potential limitations should be addressed in the present study. First, only 201 patients were included, the relatively small sample size may have reduced the statistical power of the study. Second, we only included three polymorphisms in the BARD1 gene, more polymorphisms especially the potentially functional SNPs not contained in GWASs remain to be replicated. Finally, this study was restricted to Chinese Han ethnicity subjects from Southern China, and the results should be extrapolated to other ethnic groups cautiously.

In conclusion, in the current study, we found a significant association of the BARD1 gene rs6435862 T>G and rs3768716 A>G polymorphisms with an increased neuroblastoma susceptibility for older children, children with adrenal gland-originated or late clinical stage neuroblastoma subjects in a Chinese Han population. Further prospective studies with larger sample sizes including different ethnic populations and further functional studies are required to validate our results.

Supplemental Tables 1 and 2.

Click here for additional data file.

Table 1

Logistic regression analysis of associations between BARD1 polymorphisms and neuroblastoma susceptibility.

Genotype	Cases (N=201)	Controls (N=531)	P a	Crude OR (95% CI)	P	Adjusted OR (95% CI) b	P b
rs7585356 (HWE=0.948)
GG	97 (48.26)	235 (44.26)		1.00		1.00
AG	89 (44.28)	237 (44.63)		0.91 (0.65-1.28)	0.585	0.91 (0.64-1.27)	0.567
AA	15 (7.46)	59 (11.11)		0.62 (0.33-1.14)	0.122	0.61 (0.33-1.13)	0.114
Additive			0.295	0.84 (0.65-1.08)	0.160	0.83 (0.65-1.07)	0.148
Dominant	104 (51.74)	296 (55.74)	0.332	0.85 (0.62-1.18)	0.332	0.85 (0.61-1.17)	0.315
Recessive	186 (92.54)	472 (88.89)	0.144	0.65 (0.36-1.17)	0.147	0.64 (0.35-1.16)	0.139
rs6435862 (HWE=0.205)
TT	132 (65.67)	381 (71.75)		1.00		1.00
TG	64 (31.84)	133 (25.05)		1.40 (0.97-1.99)	0.072	1.40 (0.98-2.00)	0.067
GG	5 (2.49)	17 (3.20)		0.85 (0.31-2.35)	0.752	0.84 (0.31-2.34)	0.745
Additive			0.172	1.20 (0.89-1.62)	0.222	1.21 (0.90-1.63)	0.216
Dominant	69 (34.33)	150 (28.25)	0.109	1.33 (0.94-1.88)	0.109	1.34 (0.94-1.89)	0.104
Recessive	196 (97.51)	514 (96.80)	0.614	0.77 (0.28-2.12)	0.615	0.77 (0.28-2.10)	0.604
rs3768716 (HWE=0.415)
AA	125 (62.19)	364 (68.55)		1.00		1.00
AG	69 (34.33)	148 (27.87)		1.36 (0.96-1.93)	0.087	1.38 (0.97-1.96)	0.076
GG	7 (3.48)	19 (3.58)		1.07 (0.44-2.61)	0.877	1.06 (0.43-2.57)	0.907
Additive			0.230	1.22 (0.92-1.63)	0.170	1.23 (0.92-1.64)	0.163
Dominant	76 (37.81)	167 (31.45)	0.103	1.33 (0.94-1.86)	0.103	1.34 (0.95-1.88)	0.094
Recessive	194 (96.52)	512 (96.42)	0.950	0.97 (0.40-2.35)	0.951	0.96 (0.40-2.31)	0.918
Combined effect of risk genotypes
0	49 (24.38)	129 (24.29)	0.171c	1.00		1.00
1	77 (38.31)	244 (45.95)		0.83 (0.55-1.26)	0.384	0.83 (0.54-1.25)	0.369
2	53 (26.37)	105 (19.77)		1.33 (0.83-2.12)	0.232	1.34 (0.84-2.13)	0.225
3	22 (10.95)	53 (9.98)		1.09 (0.60-1.98)	0.770	1.10 (0.60-1.99)	0.763
1-3	152 (75.62)	402 (75.71)	0.981	1.00 (0.68-1.45)	0.981	0.99 (0.68-1.45)	0.973

a χ test for genotype distributions between neuroblastoma patients and controls.

b Adjusted for age and gender.

c Additive models.

Table 2

Stratification analysis for association between BARD1 genotypes and neuroblastoma susceptibility.

Variables	rs7585356(cases/controls)		Adjusted OR a (95% CI)		P a	rs6435862 (cases/controls)		Adjusted OR a (95% CI)	P a	rs3768716 (cases/controls)		Adjusted OR a (95% CI)	P a
	GG	AG/AA				TT	TG/GG			AA	AG/GG
Age, month
<12	22/67	32/78		1.23 (0.65-2.32)	0.529	41/105	13/40	0.85 (0.41-1.77)	0.670	38/98	16/47	0.90 (0.45-1.78)	0.756
≥12	75/168	72/218		0.74 (0.50-1.08)	0.119	91/276	56/110	1.55 (1.04-2.31)	0.032	87/266	60/120	1.54 (1.04-2.28)	0.032
Gender
Females	48/102	34/131	0.55 (0.33-0.92)		0.022	53/160	29/73	1.20 (0.70-2.04)	0.504	49/150	33/83	1.22 (0.73-2.04)	0.458
Males	49/133	70/165	1.15 (0.75-1.77)		0.522	79/221	40/77	1.45 (0.92-2.30)	0.113	76/214	43/84	1.44 (0.92-2.27)	0.112
Sites of origin
Adrenal gland	15/235	15/296	0.80 (0.38-1.66)		0.543	14/381	16/150	2.94 (1.40-6.18)	0.005	14/364	16/167	2.55 (1.21-5.37)	0.014
Retroperitoneal	21/235	29/296	1.09 (0.61-1.97)		0.767	36/381	14/150	1.00 (0.52-1.91)	0.996	36/364	14/167	0.87 (0.45-1.65)	0.660
Mediastinum	43/235	37/296	0.68 (0.43-1.10)		0.114	54/381	26/150	1.22 (0.73-2.02)	0.450	51/364	29/167	1.23 (0.75-2.01)	0.410
Others	10/235	7/296	0.56 (0.21-1.49)		0.242	15/381	2/150	0.35 (0.08-1.57)	0.172	13/364	4/167	0.70 (0.22-2.18)	0.534
Clinical stages
I+II+4s	52/235	59/296	0.90 (0.60-1.36)		0.621	76/381	35/150	1.18 (0.75-1.83)	0.477	73/364	38/167	1.13 (0.73-1.75)	0.580
III+IV	41/235	42/296	0.80 (0.50-1.27)		0.347	49/381	34/150	1.75 (1.09-2.84)	0.022	47/364	36/167	1.69 (1.05-2.72)	0.031

a Adjusted for age and gender.